ERT (Philadelphia, PA) is celebrating what it describes as a significant milestone: The completion of its 150th Thorough QT clinical trial (TET).
“The TET study plays a crucial role in the development of a new pharmaceutical product," said John Blakeley, executive vice president of ERT, in a company press release. "We are very excited to have supported the industry to help improve the cardiac safety of new drugs coming to market."
With the advent of the ICH E14 Guidance in 2005, a TET has become a necessary part of the trials process for most drugs that require rigorous and robust electrocardiographic testing (ECG).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.